BerGenBio

Pre-Annual General Meeting Information • Dec 16, 2021

BerGenBio ASA: Notice of Extraordinary General Meeting

BerGenBio ASA: Notice of Extraordinary General Meeting

Bergen, Norway, 16 December 2021 - Notice is hereby given that an Extraordinary

General Meeting in BerGenBio ASA (OSE:BGBIO) will be held on 6 January 2022 at

10:00 hours (CET).

The notice, registration form and power of attorney are attached to this

release. The notice will be sent to all registered shareholders and is

available at https://www.bergenbio.com/investors/general-

meetings/ (https://www.bergenbio.com/investors/general-%20meetings/)

All shareholders are encouraged to exercise their shareholder rights. Due to the

ongoing corona virus pandemic, the Board encourages shareholders not to attend

the general meeting in person, but rather to make use of the ability to vote by

proxy.The proxy form is attached to this release and available on the Company's

website:  https://www.bergenbio.com/investors/general-meetings/

The following items are on the agenda: (i) Election of new Chair of the Board of

Directors and changes to the board (ii) Remuneration to the chair of the board.

We encourage all shareholders to register as electronical user in VPS to save

environment impact.

-Ends-

Contacts

Martin Olin, CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive, therapy resistant cancers. The

company's proprietary lead candidate, bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad phase II clinical development

programme focused on combination and single agent therapy in cancer and COVID

-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is

undergoing phase I clinical testing. In parallel, BerGenBio is developing

companion diagnostic tests to potentially identify patient populations most

likely to benefit from AXL inhibition. This is expected to facilitate more

efficient registration trials supporting a precision medicine-based

commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Suchrisks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.